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Abstract
Background: Caspofungin is a new antifungal agent with high-level activity against a number of
Candida  species including those that are resistant to azoles. Its good safety profile and low
nephrotoxicity makes it an attractive drug to treat fungal infections in patients with compromised
renal function. However, little is known about the clinical efficacy in the treatment of complicated
urinary tract infections due to Candida species such as pyonephrosis.
Case presentation: We report a case of obstructive pyonephrosis due to an azole (fluconazole
and itraconazole) resistant Candida glabrata strain that failed to respond to intravenous treatment
with caspofungin. A sustained clinical and microbiological response was only achieved after
percutaneous drainage and instillation of amphotericin B deoxycholate into the renal pelvis in
combination with intravenous liposomal amphotericin B.
Conclusion:  This case demonstrates the limitation of intravenous antifungal agents such as
caspofungin as the sole treatment of an obstructive upper urinary tract infection due to Candida
species. In order to achieve long term sustained cure from an obstructive pyonephrosis, pus and
fungal balls should be drained and an anti-fungal agent such as amphotericin B deoxycholate instilled
locally. The pharmacokinetics and role of caspofungin in the treatment of complicated Candida
urinary tract infection is reviewed.
Background
Pyonephrosis refers to infected purulent urine in an
obstructed urinary collecting system such as the renal pel-
vices. Although bacteria cause the majority of these infec-
tions,  Candida  species such as C. glabrata have been
reported to be involved in 5% of cases [1].
We describe a case of pyonephrosis complicated by candi-
daemia due to an azole (fluconazole and itraconazole)
resistant C. glabrata that had not resolved after treatment
with intravenous (iv) caspofungin. Caspofungin is a novel
antifungal agent belonging to the class of echinocandins
with good antifungal activity against Candida  species
including azole resistant strains [2]. It is recommended for
the treatment of candidaemia and other serious invasive
Candida infections [3]. The role of antifungal agents and
the importance of percutaneous nephrostomy drainage in
the conservative management of Candida pyonephrosis is
discussed.
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Case presentation
A 71-year-old lady with type II diabetes mellitus, treated
with insulin, presented in February 2004 with acute renal
failure due to bilateral ureteric obstruction and hydrone-
phrosis. Six months prior to this acute admission, the
patient was treated empirically with fluconazole for a his-
tologically proven necrotising Candida  infection of the
bladder. Her acute obstruction was managed by the inser-
tion of bilateral nephrostomy catheters. On the day of the
procedure she developed rigors, vomiting and right loin
pain despite antibiotic cover with amoxicillin (500 mg
tds). She was pyrexial (38.9°C), her inflammatory mark-
ers were increased (WBC 23.2 × 109/l, neutrophils 21.8 ×
109/l, CRP 300 mg/l) and her renal function compro-
mised (creatinine 333 μmol/l). The blood and nephros-
tomy urine cultures grew a non- albicans Candida species.
The pre-morbid history suggested that the current non-
albicans Candida isolate might be an azole-resistant strain
and on the basis of her acute renal failure, the patient was
commenced on empirical intravenous liposomal ampho-
tericin B (AmBisome 1 mg/kg/od). The organism was sub-
sequently identified as C.glabrata  with reduced
susceptibility to fluconazole and itraconazole MIC fluco-
nazole 16.0 mg/l, itraconazole 1.0 mg/l) but susceptible
to amphotericin B (MIC 1.0 mg/l), caspofungin (MIC 0.5
mg/l), voriconazole (MIC < 0.03 mg/l).
The patient was treated for four weeks with iv liposomal
amphotericin B during which time her left nephrostomy
tube was replaced by a ureteric stent. Four months later
she was readmitted to the hospital for an elective right
ureteric stent insertion but she developed a severe urosep-
sis (temperature 39.4°C, WBC 45.5 × 109/l, CRP > 300
mg/l, creatinine 407 μmol/l) during the procedure which
was abandoned. AmBisome (1 mg/kg/od) was given
shortly after the procedure but did not prevent the need
for intensive care support. Blood cultures and urostomy
urine again grew the azole resistant C.glabrata. Due to the
recurrence of Candida sepsis despite previous treatment
with amphotericin B and because of her acute renal failure
it was felt that a different class of anti-fungal agent with
good activity against C.glabrata and minimal nephrotoxic-
ity should be used. Amphotericin B was therefore stopped
after three days and replaced by iv caspofungin (70 mg
loading dose, 50 mg od). Caspofungin was continued for
12 days during which time her blood and catheter urine
became sterile and her inflammatory markers and temper-
ature normalised.
However, as the stenting of her right kidney was unsuc-
cessful, attributed to multiple intra-renal strictures and
irregularity of the urothelial outline, a percutaneous
nephrostomy tube was inserted to allow long-term drain-
age. This time AmBisome was given one day prior to the
procedure and continued for a total of 11 days during
which time no sepsis occurred. Nevertheless, nephros-
tomy fluid analysis revealed large numbers of pus and
yeast cells and again grew the azole resistant C.glabrata.
Because of the persistent C. glabrata infection of the renal
pelvices, despite treatment with iv liposomal amphoter-
icin B followed by a course of caspofungin, it was felt that
active local irrigation with amphotericin B was necessary
to reduce the fungal load and to ensure that the antifungal
agent achieved the site of infection. Five ml of conven-
tional amphotericin B (Fungizone, 200 μg/ml) was
instilled into the nephrostomy tube which was then
clamped for 30–60 minutes at a time. This procedure was
repeated four times daily for four days. A urostomy sam-
ple of urine taken 48 hours later continued to grow C. gla-
brata and treatment was therefore repeated for a further
five days in combination with iv liposomal amphotericin
B. Subsequently the urine sterilised and routine monthly
urine cultures remained negative. The patient has had no
further recurrence of the Candida infection during a 16
month follow up.
Discussion
C. glabrata is an emerging pathogen and it is now the most
common non-albicans species causing candidaemia [4].
This organism is increasingly resistant to the first line anti-
fungal agent fluconazole which poses a challenge in the
treatment of serious Candida infections [3,4]. The conven-
tional treatment of azole resistant Candida strains often
requires traditional agents such as amphotericin B, which
can cause nephrotoxicity. Caspofungin belongs to a new
group of antifungals, the echinocandins, which is highly
active against azole resistant non-albicans Candida spe-
cies. It demonstrates good activity in vitro against C. gla-
brata  with MICs ranging between of 0.19–2 μg/ml
although the drug might not always be fungicidal against
this pathogen [2,5,6].
Clinical trials with caspofungin have shown good efficacy
in the treatment of candidaemia, Candida  oesophagitis
and individual case reports have shown treatment suc-
cesses with other serious Candida infections such as endo-
carditis [6-8]. The drug is well tolerated and, due to its
principally hepatic excretion, it is safe to use in renal fail-
ure [6].
Very little is known about the clinical efficacy of caspofun-
gin in the treatment of complicated fungal urinary tract
infections such as pyonephrosis. Animal studies have
shown that caspofungin can be detected in kidney tissue
at concentrations three times that of plasma levels 24
hours after injection [9]. Similar pharmacokinetics were
reported by Stone et al. who detected 4.2% of the original
caspofungin dose in animal kidneys versus 35.2% in liver
tissue after 24 hours [10]. Experiments in mice have also
demonstrated that caspofungin can significantly reduceBMC Infectious Diseases 2006, 6:126 http://www.biomedcentral.com/1471-2334/6/126
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the C.glabrata tissue burden in kidneys at doses as low as
0.3 mg/kg/day although organ sterilization may only
occur at much higher drug doses of 5 mg/kg/day or in
combination with amphotericin B [5,11].
Unfortunately, the drug concentration in the kidney does
not reflect availability in the urine. In healthy individuals,
only a small fraction (1.44%) of the original drug can be
detected after 24 hours in the urine after a single iv dose
[10,12]. Caspofungin may therefore not be the drug of
choice in the treatment of serious urinary tract infections
although more clinical data is needed to fully assess the
role of this drug for the treatment of such infections.
Another important issue in the management of pyoneph-
rosis is the accumulation of pus and fungi in an
obstructed space, the renal pelvices. As with other
enclosed bacterial infections such as empyemas, drainage
of the pus is of fundamental importance and may explain
why systemic treatment with antifungals such as ampho-
tericin B, caspofungin or fluconazole alone have proven
to be unsuccessful [13,14].
In cases of pyonephrosis the insertion of a percutaneous
nephrostomy tube allows urinary diversion with subse-
quent improvement in renal function and also enables the
local administration of an anti-fungal drug directly to the
site of infection [15]. Our case report supports the sparse
literature suggesting that drainage via a percutaneous
nephrostomy tube combined with the local instillation in
combination with systemic use of an antifungal agent
such as caspofungin or amphotericin B is necessary to suc-
cessfully manage such an infection [13,14]. Other anti-
fungal drugs such as flucytosine or voriconazole may also
need to be considered.
Conclusion
The intravenous anti-fungal drugs such as caspofungin or
amphotericin B are useful in treating or preventing candi-
daemia during instrumentation such as insertion of neph-
rostomy tubes in cases of Candida  pyonephrosis.
However, they are unlikely to lead to a cure of this infec-
tion if used as the sole treatment. Conservative manage-
ment should also include local drainage of pus and fungi
as well as instillation of an effective antifungal agent into
the pelvices.
Abbreviations
MIC: minimal inhibitory concentration
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SS wrote the manuscript and was involved with the
patients management. CNR cared for the patient and con-
tributed to the writing of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
Written consent was obtained from the patient for publication of the study.
References
1. Ng CK, Yip SK, Sim LS, Tan BH, Wong MY, Tan BS, Htoo A: Out-
come of percutaneous nephrostomy for the management of
pyonephrosis.  Asian J Surg 2002, 25:215-9.
2. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG: In
vitro activity of new echinocandin antifungal, MK-0991
against common and uncommon clinical isolates of Candida
species.  Eur J Clin Microbiol Infect Dis 1999, 18:302-304.
3. Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of
candidiasis.  Clin Infect Dis 2004, 38:161-189.
4. Schelenz S, Gransden WR: Candidaemia in a London teaching
hospital: analysis of 128 cases over a 7-year period.  Mycoses
2003, 46:390-6.
5. Barchiesi F, Spreghini E, Tomassetti S, Arzeni D, Giannini D, Scalise G:
Comparison of the fungicidal activities of caspofungin and
amphotericin B against Candida glabrata.  Antimicrob Agents
Chemother 2005, 49:4989-92.
6. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya
L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J: Caspofun-
gin Invasive Candidiasis Study Group. Comparison of caspo-
fungin and amphotericin B for invasive candidiasis.  N Engl J
Med 2002, 347:2020-2029.
7. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA,
Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized
double-blind study of caspofungin versus fluconazole for the
treatment of esophageal candidiasis.  Am J Med 2002,
113:294-299.
8. Lye DC, Hughes A, O'Brien D, Athan E: Candida glabrata pros-
thetic valve endocarditis treated successfully with flucona-
zole plus caspofungin without surgery: a case report and
literature review.  Eur J Clin Microbiol Infect Dis 2005, 24:753-755.
9. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski
JF, Kropp H: Preliminary animal pharmacokinetics of the
parenteral antifungal agent MK-0991 (L-743,872).  Antimicrob
Agents Chemother 1997, 41:2339-2344.
10. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM,
Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Las-
seter KC: Disposition of caspofungin: role of distribution in
determining pharmacokinetics in plasma.  Antimicrob Agents
Chemother 2004, 48:815-23.
11. Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Gian-
nini D, Rinaldi MG, Scalise G: Caspofungin in combination with
amphotericin B against Candida glabrata.  Antimicrob Agents
Chemother 2005, 49:2546-9.
12. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D,
Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pear-
son PG, Baillie TA: Metabolites of caspofungin acetate, a
potent antifungal agent, in human plasma and urine.  Drug
Metab Dispos 2000, 28:1274-1278.
13. Arend SM, Kuijper EJ, de Vaal BJ, de Fijter JW, Van't Wout JW: Suc-
cessful treatment of fungus balls due to fluconazole-resistant
Candida sake obstructing ureter stents in a renal transplant
patient.  Eur J Clin Microbiol Infect Dis 2005, 20:1-3.
14. Clark MA, Gaunt T, Czachor JS: The use of fluconazole as a local
irrigant for nephrostomy tubes.  Mil Med 1999, 164:239-241.
15. Bell DA, Rose SC, Starr NK, Jaffe RB, Miller FJ Jr: Percutaneous
nephrostomy for nonoperative management of fungal uri-
nary tract infections.  J Vasc Interv Radiol 1993, 4:311-5.
Pre-publication history
The pre-publication history for this paper can be accessed
here:Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2006, 6:126 http://www.biomedcentral.com/1471-2334/6/126
Page 4 of 4
(page number not for citation purposes)
http://www.biomedcentral.com/1471-2334/6/126/pre
pub